Senior Scientist, Chemical Development and Manufacturing

Senior Scientist, Chemical Development and Manufacturing

Who we are:

At Agios, we are fueled by connections to transform rare diseases. We foster an inclusive, collaborative culture – one that sparks bold thinking and strengthens our connections with each other and with the rare disease communities we serve. We embrace diverse backgrounds with respect, active listening, and a commitment to inclusion – because our differences shape how we hire, collaborate, and innovate.

Our team’s proven track record of executional excellence, combined with our depth of expertise and dedication, enables us to develop innovative medicines that reflect the priorities of rare disease communities. Our commitment is more than scientific – it’s deeply personal, grounded in the meaningful connections we have built. To learn more, visit  and follow Agios on Linked In and X.

Agios is seeking a talented and highly motivated Senior Scientist to join the Chemical Development & Manufacturing (CDM) team. This is a bench-forward, technically deep role for a scientist who thrives in the laboratory and wants to build expertise across the full spectrum of small molecule drug substance development—from early process design through technology transfer and clinical manufacturing.

Reporting to and closely supporting a CDM SME, you will serve as a key scientific contributor on an assigned small molecule program. Your primary responsibility is hands‑on laboratory execution: generating the experimental data that drives process understanding, informs solid‑state decisions, demonstrates scale‑up feasibility, and enables the team to advance with confidence through each stage of development. You will be the bench anchoring the program.

• Design, execute, and interpret laboratory experiments to develop robust, scalable synthetic routes for small molecule drug substances; apply mechanistic understanding to guide reaction optimization and troubleshooting.
• Conduct structured process optimization studies (including DOE‑driven parameter screening and Design Space mapping) to define critical process parameters and establish proven acceptable ranges.
• Generate high‑quality impurity profiles; identify, synthesize, and characterize process‑related impurities; develop and implement control strategies to meet ICH Q3A/Q3C requirements.
• Document and transfer to external CDMOs kilo‑lab and pilot‑scale reactions under GMP or GMP‑like conditions; evaluate equipment performance, mixing dynamics, heat transfer behavior, and process scalability with increasing batch sizes.
• Investigate and resolve process‑related manufacturing deviations, atypical results, and OOS observations through systematic root cause analysis and corrective action experiments at the bench.
• Explore and apply advanced synthetic technologies to accelerate development—including continuous flow chemistry, in‑line process analytics (PAT), and computational tools for reaction and process modeling.

• Conduct polymorph, salt, co‑crystal, and solvate screening campaigns to identify and evaluate drug substance solid forms with appropriate physical, chemical, and stability properties for development.
• Design and execute crystallization development studies—including solvent system evaluation, antisolvent addition, seeding strategies, and cooling profiles—to deliver a controlled, reproducible, and scalable crystallization process.
• Characterize solid forms using standard analytical techniques (XRPD, DSC, TGA, PLM, dynamic vapor sorption, NMR) and interpret data in the context of form selection and process design.
• Develop particle engineering strategies to achieve target particle size distribution, morphology, and bulk density requirements critical for downstream processing and formulation compatibility.
• Assess solid form stability under stressed and ICH‑aligned conditions; support selection of the preferred commercial form through integrated analysis of processability, stability, and bioavailability data.
• Maintain and transfer crystallization processes to CDMO partners in collaboration…